PMGC Holdings (ELAB) Other financing activities (2023 - 2025)

PMGC Holdings (ELAB) posted Other financing activities of -$186615.0 for Q4 2025, down 187.19% sequentially from $214030.0 in Q3 2025.

PMGC Holdings (ELAB) Other financing activities (2023 - 2025) Analysis & Trends

PMGC Holdings has reported Other financing activities for 2 years, with the latest figure at -$186615.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to -$186615.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
Other financing activities eased to -$186615.0 in Q4 2025 per ELAB's latest filing, from $214030.0 in the prior quarter.
Over five years, Other financing activities peaked at $1.9 million in Q1 2025 and troughed at -$454744.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	PMGC Holdings	31.22 Mn	12.43 Mn	385,691.00

Download Data